Across TCGA pan-cancer cohorts, NXPH4 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of NXPH4’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where NXPH4 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types NXPH4 is over-expressed in tumor.
LUAD and LSCC are the cancer types where NXPH4 tumor–normal differential expression is most reproducible.